Sign up online today & collaborate
or click here to find out more
Almac Discovery and Genentech, Roche’s subsidiary, joined forces to defeat cancer. The partners have set their eyes on a novel target with an important role in key oncogenic pathways. In order to do so, Almac is set to receive an upfront payment of €12.9M and up to €311M in payment based on the development of the program.
Ubiquitin-specific proteases are emerging as potential targets in several diseases, including cancer. However, inhibitors of ubiquitin specific proteases have been difficult to identify despite significant efforts from both pharmaceutical and biotech companies.
Almac Discovery’s novel, potent and selective small molecule inhibitors will be the starting point of a two-year joint research program funded by Genentech. The California-based firm is an undoubted leader in oncology development and, thanks to its deep knowledge in the ubiquitin field, is the perfect complement for the Northern Irish company.For more click here